Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Liposome composition for improved intracellular delivery of a therapeutic agent

a technology of liposomes and compositions, applied in the direction of pharmaceutical delivery mechanisms, antibody ingredients, medical ingredients, etc., can solve the problems of the loss of the desired rapid destabilization of the liposome bilayer, and the accompanying rapid release of the entrapped agent into the cell. achieve the effect of increasing the accumulation of therapeutic agents and increasing the accumulation of agents

Inactive Publication Date: 2006-10-26
ZALIPSKY SAMUEL +2
View PDF11 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0018] (iii) internalization of the liposome by the target cell. Such administering is effective to achieve at least a two-fold higher intracellular cytotoxicity of the agent, relative to intracellular concentration of the drug delivered by similar liposomes lacking the releasable bond and / or the targeting ligand.
[0020] In another aspect, the invention relates to a method for increasing accumulation of a therapeutic agent in cellular nuclei by providing liposomes as described above and administering the liposomes to achieve (i) cleavage of the releasable bond, thereby releasing all or a portion of the hydrophilic polymer chains; (ii) binding of the ligand to a target cell, where the binding occurs prior to or subsequent to the cleavage; and (iii) internalization of the liposome by the target cell. Such administering is effective to achieve at least a two-fold higher accumulation of the agent in the nucleus of the target cell, when compared to intracellular concentration of the agent delivered by similar liposomes lacking the releasable bond and / or the targeting ligand.

Problems solved by technology

To date, however, success in achieving intracellular delivery of a liposome-entrapped agent has been limited for a variety of reasons.
Another reason is the inherent difficulty in delivering a molecule, in particular a large or a charged molecule, into the cellular cytoplasm and / or the nucleus.
However, addition of PEG-derivatized lipids attenuates the pH-sensitivity of the liposomes, resulting in a loss of the desired rapid destabilization of the liposome bilayer and accompanying rapid release of the entrapped agent into the cell.
This approach suffers from the disadvantage of releasing the entrapped liposome contents extracellularly.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liposome composition for improved intracellular delivery of a therapeutic agent
  • Liposome composition for improved intracellular delivery of a therapeutic agent
  • Liposome composition for improved intracellular delivery of a therapeutic agent

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of pH-Sensitive and Non-pH-Sensitive Liposomes

[0129] Sterically stabilized pH-sensitive liposomes were prepared from a mixture of dioleoylphosphatidylethanolamine (DOPE) or DOPE / CHEMS (cholesteryl hemisuccinate) and either mPEG-DSPE or mPEG-S-S-DSPE (prepared as described in Kirpotin et al.) and DSPE-PEG-maleimide (Mal-PEG-DSPE; prepared as described in U.S. Pat. No. 6,326,353) according to the lipid molar ratios of the desired formulations. The desired lipid mixture was dissolved in chloroform and dried as a thin film by rotation under reduced pressure using a rotary evaporator. The dried lipid film was hydrated by addition of an aqueous buffer to form liposomes. The liposomes were sized by sequential extrusion through a series of Nucleopore polycarbonate filters with pore size ranging from 0.2 to 0.08 μm, using a Lipex Extruder (Lipex Biomembranes, Vancouver, BC). The mean diameter of liposomes was determined by dynamic light scattering using a Brookhaven BI-90 Partic...

example 2

Antibody Coupling to Pre-Formed Liposomes

[0132] Coupling of anti-CD19 mAb to maleimide (Mal)-PEG-DSPE on the liposomes was carried out according to a previously described method (Lopes de Menezes et al., J.Liposome Res., 9:199 (1999)), using 125I-labeled anti-CD19 mAb as a tracer.

[0133] Antibodies were first activated with Traut's reagent (2-iminothiolane) at a molar ratio of 20:1 (Traut's: IgG), at a concentration of 10 mg IgG / ml buffer for 1 h at 25° C. in HEPES buffer, pH 8.0 (25 mM HEPES, 140 mM NaCl). Unreacted Traut's reagent was removed using a G-50 column. The coupling reaction was run at an IgG to phospholipid molar ratio of 1:2000, under argon atmosphere for 18 h at 25° C. Uncoupled Ab was removed from the liposomes by passing the coupling mixture through a Sepharose CL-4B column in HEPES buffer, pH 7.4. The coupling efficiency was on average 80%.

[0134] All mAb densities were routinely in the range of 30-60 μg anti-CD19 / μmol phospholipid for in vivo experiments and 65-8...

example 3

Leakage of Liposome-Entrapped Fluorescent Dye or Liposome-Entrapped Doxorubicin in Buffer

[0135] Leakage of entrapped HPTS-DPX from various formulations of DOPE or DOPE / CHEMS liposomes was evaluated by monitoring the release of entrapped solute using a fluorescence-dequenching assay. HPTS was passively loaded into the liposomes as the water-soluble (but fluorescence-quenched) complex, HPTS-DPX. When HPTS-DPX leaks from the liposomes; it dissociated into free HPTS and DPX, increasing the HPTS fluorescence when excited at 413 nM. The DOPE and DOPE / CHEMS formulations tested were:

Lipid ComponentsMolar RatioDOPE1DOPE / mPEG-DSPE1:0.05DOPE / mPEG-S-S-DSPE1:0.05DOPE / CHEMs6:4DOPE / CHEMS / mPEG-DSPE6:4:0.3DOPE / CHEMS / mPEG-S-S-DSPE6:4:03

[0136] Liposomes containing entrapped HPTS-DPX were passed over a Sephadex G-50 column immediately prior to use to remove any residual free dye or drug. Fifty (50) μl of liposomes containing entrapped dye (HPTS-DPX) or doxorubicin were incubated at 0.5 mM final PL c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
pKaaaaaaaaaaa
Login to View More

Abstract

A liposomal composition and a method of using the same for achieving intracellular delivery of a liposome-entrapped agent is described. The liposomes are composed of a pH sensitive lipid and include a targeting ligand to direct the liposomes to a target cell. The liposomes also include a stabilizing component, such a polymer-derivatized lipid, where the polymer is attached to the lipid by a releasable linkage. Administration of the liposomes results in cellular internalization and destabilization of the liposome for intracellular delivery of the entrapped agent.

Description

[0001] This application is a continuation of U.S. application Ser. No. 10 / 108,154, filed Mar. 26, 2002, which claims the benefit of U.S. Provisional Application No. 60 / 278,869, filed Mar. 26, 2001.FIELD OF INVENTION [0002] The present invention relates to liposomal compositions designed for improved intracellular delivery of an entrapped agent. More specifically, the invention relates to compositions and methods for increasing the intracellular cytotoxicity of a liposome-entrapped agent. BACKGROUND OF THE INVENTION [0003] Liposomes have long been considered possible vehicles for delivery of therapeutic agents intracellularly. To date, however, success in achieving intracellular delivery of a liposome-entrapped agent has been limited for a variety of reasons. One reason is that liposomes, after systemic administration to the bloodstream, are rapidly removed from circulation by the reticuloendothelial system. Another reason is the inherent difficulty in delivering a molecule, in parti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K9/127A61K9/133A61K9/54A61K47/24A61K47/28A61K47/30A61K47/34A61K47/46A61K47/48
CPCA61K9/1271A61K47/48823A61K9/1272A61K47/6913
Inventor ZALIPSKY, SAMUELALLEN, THERESA M.HUANG, SHI KUN
Owner ZALIPSKY SAMUEL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com